Jascayd (nerandomilast) for the Treatment of Idiopathic Pulmonary Fibrosis...
Jascayd® is a PDE4 inhibitor indicated to treat adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The post Jascayd (nerandomilast) for the Treatment of...
View ArticleModeyso (dordaviprone) for the Treatment of Diffuse Midline Glioma, US
Modeyso™ (dordaviprone) is indicated for the treatment of adult and paediatric patients aged one year and older with diffuse midline glioma. The post Modeyso (dordaviprone) for the Treatment of Diffuse...
View ArticleCinnaGen Enters EU Market with EMA Approval for Zandoriah®
The post CinnaGen Enters EU Market with EMA Approval for Zandoriah® appeared first on Clinical Trials Arena.
View ArticleSunlenca (Lenacapavir) for the Treatment of HIV-1 Infection, US
Sunlenca (lenacapavir) is a first-in-class, long-acting HIV capsid inhibitor approved for the treatment of HIV-1 infection. The post Sunlenca (Lenacapavir) for the Treatment of HIV-1 Infection, US...
View ArticleFilspari (sparsentan) for the Reduction of Proteinuria in IgA Nephropathy, US
Filspari (sparsentan) is a first-of-its-kind, oral non-immunosuppressive therapy indicated for reducing proteinuria in IgA nephropathy. The post Filspari (sparsentan) for the Reduction of Proteinuria...
View ArticleGEMTESA for the Treatment of Overactive Bladder, US
GEMTESA (vibegron) is an oral medication indicated for the treatment of OAB with signs of UUI, urgency and urinary frequency in adults. The post GEMTESA for the Treatment of Overactive Bladder, US...
View ArticleTezspire (tezepelumab-ekko) for the Treatment of Severe Asthma, US
Tezspire (tezepelumab-ekko) is a first-in-class human monoclonal antibody indicated for add-on maintenance treatment of severe asthma. The post Tezspire (tezepelumab-ekko) for the Treatment of Severe...
View ArticleELAHERE for the Treatment of Ovarian Cancer, US
ELAHERE® is a novel ADC indicated for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian cancer. The post ELAHERE for the Treatment of Ovarian Cancer, US appeared...
View ArticleClik here to view.
XOLREMDI (mavorixafor) for the Treatment of WHIM Syndrome, US
XOLREMDI (mavorixafor), a CXCR4 antagonist, is the first approved therapy indicated to treat patients with WHIM syndrome.The post XOLREMDI (mavorixafor) for the Treatment of WHIM Syndrome, US appeared...
View ArticleClik here to view.
ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of HER2-positive...
ENHERTU is the first antibody-drug conjugate available for adults to treat locally advanced or metastatic HER2-positive gastric cancer.The post ENHERTU (fam-trastuzumab deruxtecan-nxki) for the...
View Article
![vaultboy – ARE YOU EVER COMING BACK? [iTunes Plus M4A]](http://is1-ssl.mzstatic.com/image/thumb/Music221/v4/91/18/0e/91180e72-61ab-e1e7-2a35-dd2542b571ce/612891119237.jpg/296x296bb.webp)
